
Ninety-Seven Per Cent of Canadians Say Eye Health is Crucial to Wellbeing but More Education is Needed to Keep Eyes Healthy: COS Survey Français
Released during National Vision Health Month, the findings highlight a strong national commitment to vision care and an opportunity to empower Canadians with more education.
TORONTO, May 2, 2025 /CNW/ - The ability to see impacts everything we do, and according to a recent national survey by the Canadian Ophthalmological Society (COS), the vast majority (97 per cent) of Canadians consider eye health a crucial part of their overall well-being. Yet, only half feel they know what contributes to the health of their eyes. As National Vision Health Month kicks off, COS emphasizes the importance of continued education to raise awareness, promote regular eye exams, and improve access to quality vision care for all Canadians.
Canadians Now Recognize Eye Health as a Top Priority, but Knowledge Gaps Exist
While most Canadians (83 per cent) say they prioritize their vision health, half feel familiar with treatment options for serious eye problems (53 per cent) or eye diseases such as cataracts (52 per cent) for example, a leading cause of blindness. Among those aged 55 and older, 68 per cent say they're knowledgeable about the symptoms and early signs of the condition, compared to 41 per cent of younger Canadians aged 18 to 34, even though cataracts can occur at any age.
"While Canadians overwhelmingly recognize the importance of eye health, many remain unaware of the eye diseases they may be at risk for and the symptoms to watch for," said Dr. Mona Dagher, president of the Canadian Ophthalmological Society. "These survey findings reinforce the need for better public education so people can take proactive steps, including regular eye exams, to protect their vision."
Additional insights:
Canadians support innovations in eye care, and 92 per cent agree that access to the latest advancements is essential. Three-quarters (75 per cent) feel they have access to these innovations, but only 52 per cent feel comfortable with AI-assisted diagnostics.
Concerns about screen time's effects on children's eye health remain high, with 82 per cent of Canadians expressing worry, on par with 2024.
Thirty-eight per cent say extreme weather negatively impacted their eye health in the past year, indicating environmental factors are also an increasing concern.
While 56 per cent of Canadians correctly identify ophthalmologists as medical doctors with specialized surgical training, 17 per cent are unaware of what they do, and 28 per cent misidentify their role.
Advocacy and Policy Action Needed
Despite growing awareness in general, 56 per cent of Canadians feel that eye health does not receive the same level of attention as other health priorities in the healthcare system. This perception highlights the need for greater advocacy and policy action to ensure that eye health is addressed at the national level.
"There's a clear call to action," said Dr. Nina Ahuja, chair of the Council on Advocacy for COS. "The passage of Bill C-284, the National Eye Care Strategy Act, is an important step forward. These findings reinforce our commitment to advancing vision health and ensuring access to optimal eye care for all Canadians."
To learn more about the role of an ophthalmologist, major eye diseases and to get information on overall eye health, visit seethepossibilities.ca.
About the Survey
These are some of the findings of an Ipsos poll conducted between March 20 and March 23, on behalf of the Canadian Ophthalmological Society. For this survey, a sample of 1,501 Canadians aged 18+ were interviewed online. Sample was sourced from the Ipsos panel. Weighting was employed to balance demographics to ensure that the sample's composition reflects that of the adult population according to Census data and to provide results intended to approximate the sample universe. The precision of Ipsos online polls is measured using a credibility interval. In this case, the poll is accurate to within ±3.1 percentage points, 19 times out of 20, had all Canadians been polled. The credibility interval will be wider among subsets of the population.
About Canadian Ophthalmological Society
The Canadian Ophthalmological Society (COS) is the national authority on eye and vision care in Canada. We are dedicated to ensuring optimal medical and surgical eye care by promoting excellence in ophthalmology and supporting our 900+ members and 200 residents. COS collaborates with government, specialty societies, academic communities (ACUPO), provincial partners, and patient groups to advocate for eye health policy. As an accredited CPD provider through the RCPSC and a CMA affiliate, COS is committed to advancing eye care. Learn more at cos-sco.ca.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Cision Canada
13 hours ago
- Cision Canada
IDC Report: Huawei Ranks No.1 in Global Wrist-Worn Market in Q1
H u awei wearable devices Surpassed 200 Million Cumulative Shipments SHENZHEN, China, June 14, 2025 /CNW/ -- According to the latest IDC Worldwide Quarterly Wearable Device Tracker data, Huawei ascended to the top position in the global wrist-worn device market in Q1 2025, while maintaining robust growth momentum and retaining its leadership in shipment volume within China. Additionally, as of 5 June 2025, Huawei's cumulative global wearable shipments have exceeded 200 million units. Five Product Series Catering to Global Users' Diverse Scenario Needs Huawei wearables integrate fashionable design, professional and comprehensive sports and health features, and efficient, practical smart experiences. Tailored to different user needs, Huawei has developed five product series to fulfil the diverse scenario requirements of all user groups—spanning smart living, scientific exercise, and health management. The HUAWEI WATCH Series incorporates cutting-edge smart technology, featuring standalone calling capabilities and smart vehicle control functions to enable an efficient, intelligent lifestyle. The newly launched HUAWEI WATCH 5 delivers enhanced intelligence, efficiency and convenience. Equipped with the innovative multi-sensing X-TAP technology, it unlocks new dimensions in health monitoring and tactile interaction. The HUAWEI WATCH FIT Series fulfils lightweight wear needs through its slim design and extensive sports functions, allowing users to fully enjoy daily life. Meanwhile, the HUAWEI WATCH GT Series combines exceptional battery life with fashionable aesthetics and professional sports health features, serving as a comprehensive wrist-worn fitness coach. For users who push boundaries and challenge extremes, the HUAWEI WATCH Ultimate Series delivers ultimate reliability with its rugged construction, advanced sports modes including 100-metre professional diving and outdoor expedition features, as well as advanced golf course mode, to bring cater to users' needs. Additionally, addressing hypertension management challenges, Huawei innovatively broke through wrist-based blood pressure technology to launch the HUAWEI WATCH D Series. Through its breakthrough 24-hour dynamic blood pressure monitoring function, it helps users measure and manage blood pressure anytime, anywhere, integrating professional-grade blood pressure health guardianship into daily life. Technological Innovation Driving Breakthroughs in Sports Health Technology Behind the satisfaction of users' sports health management needs lies Huawei wearables' continuous innovation investment. Huawei has established three Health Labs globally, leveraging capabilities from over ten Huawei research institutes to relentlessly explore the frontiers of sports health technology. In 2024, Huawei launched its new digital health & fitness paradigm—TruSense System—achieving higher accuracy and speed in vital sign data monitoring. In 2025, the TruSense System was upgraded again, fusing the advantages of fingertip and wrist detection to deliver a fuller, more accurate, and faster health monitoring experience, including 10-second fingertip blood oxygen readings and an increase in micro-body measurement indicators to 17 items. In the field of blood pressure management, Huawei pioneered the launch of the HUAWEI WATCH D, a wrist-based blood pressure monitor that obtained Class II medical device registration certification in China. Now this innovation included in the "Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision)". As of now, Huawei wearable devices have obtained 7 domestic medical certifications and medical device certificates in 13 overseas countries/regions, with nearly 1000 patent applications in the smart wearables field. Huawei has collaborated with over 160 global professional institutions, conducted 300+ health research projects, and attracted over 17 million users to participate in health studies. Huawei accompanies global users to build sports health lifestyles together. In September 2023, Huawei initiated the "Light Up Your Rings" campaign, which has seen over 6 million global users participate, lighting up rings over 300 million times. In 2025, the fully upgraded "Active Rings" initiative was introduced, inspiring global users to move joyfully anytime, anywhere with Huawei wearables. The Active Rings campaign has already been held in Germany, Spain, and China, and beyond, where consumers jointly enjoyed active moments. It will progressively launch in APAC, Latin America, the Middle East, and other regions in the future.


Cision Canada
a day ago
- Cision Canada
Innocan Pharma Highlights Breakthrough Narrative Review on Liposomal Synthetic CBD for Chronic Pain: A Novel Non-Opioid Analgesic Approach
HERZLIYA, Israel and CALGARY, AB, June 13, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries proudly announces the third party publication of a peer-reviewed narrative review in Cureus journal titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: The article discusses the therapeutic potential of long-acting synthetic cannabidiol (CBD) in addressing chronic pain—an urgent global health challenge for which safer, more effective treatments are desperately needed. Co-authored by leading pain specialists from institutions such as Johns Hopkins University and NYU School of Medicine, the review highlights that synthetic CBD administered through extended-release formulations could offer a well-tolerated, non-opioid analgesic alternative with the potential to significantly reduce reliance on addictive opioids. Chronic pain affects over 24% of adults in the United States alone, placing a significant burden on patients, healthcare systems, and economies*. Yet, long-term treatment options remain inadequate. NSAIDs pose cumulative toxicity risks, and opioids—while effective—present serious concerns including tolerance, dependency, and overdose risk. Globally, opioid misuse results in over 100,000 deaths annually (DOI: 10.1016/ The U.S. Food and Drug Administration (FDA) has emphasized the critical need for novel, non-addictive pain therapies through its "Guidance for Industry: Non-Opioid Analgesic Development Programs". Innocan's proprietary LPT-CBD platform is uniquely positioned to align with this regulatory focus. LPT-CBD is an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by various animal studies, LPT-CBD produces steady CBD plasma levels for up to four weeks, delivers prolonged pain relief, and is well tolerated, offering a promising alternative to current opioid medication and abuse. Innocan has initiated regulatory submissions in support of advancing LPT-CBD into human clinical trials. This progress marks a pivotal step toward realizing a first-in-class, non-opioid analgesic therapy tailored for the complexities of chronic pain management. "This publication underscores the urgent need for innovative, non-opioid analgesics that offer long-lasting efficacy," said Dr. Paul J. Christo, Associate Professor and Chief of the Division of Pain Medicine at the Johns Hopkins University School of Medicine and co-author of the article. "Liposomal synthetic CBD could offer a safe and scalable solution for a variety of painful conditions." "Given the current addiction crisis, there is an immediate need to replace opioids with safer, effective alternatives," noted Dr. Eugene Vortsman, Clinical Director of Addiction Medicine and Disease Management at Northwell Health and co-author of the article. "Long-acting synthetic CBD has real potential to shift the paradigm." Iris Bincovich, Chief Executive Officer of Innocan added:"We are thrilled by this breakthrough publication. Innocan is fully committed to advancing LPT-CBD toward clinical development, with the goal of delivering an innovative and safe non-opioid analgesic solution for chronic pain management." Reference Opioid crisis: addiction, overprescription, and insufficient primary prevention, The Lancet Regional Health – Americas 2023;23: 100557. DOI: 10.1016/ , Eugene Vortsman, Christopher Gharibo, Jo Ann K. LeQuang, Joseph V. Pergolizzi. Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review. Cureus Journal of Medical Science. DOI: 10.7759/cureus.81577 About Innocan: Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales. Contact Information: For Innocan Pharma Corporation: Iris Bincovich, CEO +1 5162104025 +972-54-3012842 +442037699377 [email protected] NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Caution Regarding Forward-Looking Information Certain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.


Global News
a day ago
- Global News
Canada's top doctor Theresa Tam to leave role June 20
Dr. Theresa Tam's time as Canada's top doctor is set to come to an end next week, the Public Health Agency of Canada says. Tam has served as Canada's chief public health officer since June 2017. PHAC said she would leave the role once her mandate finishes on June 20. A pediatric infectious diseases physician by training, Tam became a household name during the COVID-19 pandemic, providing guidance to Canadians on how to protect themselves from the disease. 2:05 Health Matters: Canadians urged to get second mpox dose amid global rise in cases The job was posted earlier this year for prospective applicants to apply, though a new public health officer has yet to be named. Story continues below advertisement Tam has been with the federal public health team since 1998, when measles was first eliminated, and told The Canadian Press it's concerning that the virus had returned. Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy Tam said she was confident the country could stop domestic transmission once again through immunization. She added that she plans to think about new opportunities following the end of her time in the role, and will spend more time with family, as well as get back to her passions, like playing music and long-distance running. — with files from The Canadian Press